Drug Trial Radar · NCT00174642
Opposing Step-by-step Insulin Reinforcement to Intensified Strategy
Last checked: Nov 20, 2026Latest source record: Sep 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
811
Actual
Start
Dec 2004
Primary completion
Dec 2008
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objectives : * To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus metformin combined with 3 bolus of insulin glulisine (Arm 1), in type 2 diabetes mellitus patients poorly controlled on basal insulin therapy with oral antidiabetic drugs. * To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus metformin and insulin secretagogue (sulfonylurea or glinide) combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 3), in type 2 diabetes mellitus patients poorly controlled on basal insulin therapy with oral antidiabetic drugs. Secondary objectives : * To compare between the 3 treatment groups: evolution of HbA1c over time, percentage of subjects with HbA1c \<= 7% at the end of the study, evolution of blood glucose profiles, incidence of hypoglycemia, insulin doses, evolution of body weight and treatment satisfaction.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin GlargineDrug
One daily injection in the evening. 100 U/ml
Insulin GlulisineDrug
Given immediately before each of the three main meals. 100 U/ml
MetforminDrug
At same dosages as the previous treatment
insulin secretagogueDrug
sulfonylurea or glinide
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: From the beginning to the end of the study
- 24-hour blood glucose levelsTime frame: From the beginning to the end of the study
- symptomatic hypoglycemia (diurnal and nocturnal)Time frame: From the beginning to the end of the study
- Severe hypoglycemia (diurnal and nocturnal),Time frame: From the beginning to the end of the study
- Insulin dosesTime frame: From the beginning to the end of the study
Locations
18 sites in 18 countries. Site status is shown where the registry gives one.
Sanofi-Aventis
Brussels, Belgium
Sanofi-Aventis
Paris, France
Sanofi-Aventis
Berlin, Germany
Sanofi-Aventis
Athens, Greece
Sanofi-Aventis
Budapest, Hungary
Sanofi-Aventis
Dublin, Ireland
Sanofi-Aventis
Milan, Italy
Sanofi-Aventis
Vilnius, Lithuania
Sanofi-Aventis
México, Mexico
Sanofi-Aventis
Gouda, Netherlands
Sanofi-Aventis
Warsaw, Poland
Sanofi-Aventis
Moscow, Russia
Sanofi-Aventis
Seoul, South Korea
Sanofi-Aventis
Barcelona, Spain
Sanofi-Aventis
Stockholm, Sweden
Sanofi-Aventis
Taipei, Taiwan
Sanofi-Aventis
Istanbul, Turkey (Türkiye)
Sanofi-Aventis
Guildford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.